← Tata Mutual Fund

Tata Nifty MidSmall Healthcare Index Fund - Direct Plan - Growth

Index/ETF Data as of Apr 2026 Comparing Mar 2026 → Apr 2026
Share: WhatsApp X
Stocks Held
30
Apr 2026
Equity Holdings
₹163.90 Cr
Equity only, excl. debt & cash
Top 5 Weight
39.2%
Moderate
Top 10 Weight
60.7%
High concentration
Changes
30
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
77.2% of portfolio
📋 What Happened This Month Among existing holdings, Fortis Healthcare Limited saw the biggest increase — now at 8.50% of the portfolio. Lupin Limited was trimmed the most, now at 9.88%. Lupin Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 77.2%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Feb 2026 Mar 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 76.3% 78.0% +1.6%
Healthcare Services 24.2% 21.0% -3.1%
Healthcare Equipment & Supplies 0.9% 0.9% 0.0%
Mar 2026 Apr 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 78.0% 77.2% -0.7%
Healthcare Services 21.0% 21.8% +0.8%
Healthcare Equipment & Supplies 0.9% 1.0% +0.2%
Biggest Add
Fortis Healthcare Limited
+0.62% · now 8.50%
Biggest Trim
Lupin Limited
-0.79% · now 9.88%

What Changed?

Comparing Mar 2026 → Apr 2026

Mar 2026 Apr 2026
↑ 16 Increased ↓ 14 Decreased
#StockSectorMar 2026Apr 2026Change
1
Fortis Healthcare Limited
₹13.92 Cr
Healthcare Services 7.88% 8.50% +0.62%
2
Cohance Lifesciences Limited
₹2.28 Cr
Pharmaceuticals & Biotechnology 0.93% 1.39% +0.46%
3
Neuland Laboratories Limited
₹3.74 Cr
Pharmaceuticals & Biotechnology 1.97% 2.29% +0.32%
4
Glenmark Pharmaceuticals Limited
₹10.49 Cr
Pharmaceuticals & Biotechnology 6.10% 6.40% +0.30%
5
Laurus Labs Limited
₹12.40 Cr
Pharmaceuticals & Biotechnology 7.34% 7.57% +0.23%
6
Wockhardt Limited
₹3.34 Cr
Pharmaceuticals & Biotechnology 1.85% 2.04% +0.19%
7
Mankind Pharma Limited
₹7.36 Cr
Pharmaceuticals & Biotechnology 4.32% 4.49% +0.17%
8
Piramal Pharma Limited
₹2.90 Cr
Pharmaceuticals & Biotechnology 1.61% 1.77% +0.16%
9
Syngene International Limited
₹2.57 Cr
Healthcare Services 1.41% 1.57% +0.16%
10
Poly Medicure Limited
₹1.67 Cr
Healthcare Equipment & Supplies 0.86% 1.02% +0.16%
#StockSectorMar 2026Apr 2026Change
1
Lupin Limited
₹16.18 Cr
Pharmaceuticals & Biotechnology 10.67% 9.88% -0.79%
2
IPCA Laboratories Limited
₹6.15 Cr
Pharmaceuticals & Biotechnology 4.23% 3.76% -0.47%
3
Biocon Limited
₹7.43 Cr
Pharmaceuticals & Biotechnology 4.90% 4.54% -0.36%
4
Alkem Laboratories Limited
₹9.15 Cr
Pharmaceuticals & Biotechnology 5.90% 5.58% -0.32%
5
JB Chemicals & Pharmaceuticals Limited
₹4.84 Cr
Pharmaceuticals & Biotechnology 3.21% 2.96% -0.25%
6
Abbott India Limited
₹3.83 Cr
Pharmaceuticals & Biotechnology 2.56% 2.34% -0.22%
7
Ajanta Pharma Limited
₹3.44 Cr
Pharmaceuticals & Biotechnology 2.25% 2.10% -0.15%
8
Gland Pharma Limited
₹4.03 Cr
Pharmaceuticals & Biotechnology 2.57% 2.46% -0.11%
9
Pfizer Limited
₹2.07 Cr
Pharmaceuticals & Biotechnology 1.36% 1.26% -0.10%
10
Aster DM Healthcare Limited
₹5.14 Cr
Healthcare Services 3.23% 3.14% -0.09%

Full Portfolio

30 stocks — Apr 2026

# Stock Sector Cap Weight & Value
1
₹16.18 Cr
Pharmaceuticals & Biotechnology
9.88%
2
₹13.92 Cr
Healthcare Services
8.50%
3
₹12.40 Cr
Pharmaceuticals & Biotechnology
7.57%
4
₹11.24 Cr
Pharmaceuticals & Biotechnology
6.86%
5
₹10.49 Cr
Pharmaceuticals & Biotechnology
6.40%
6
₹9.15 Cr
Pharmaceuticals & Biotechnology
5.58%
7
₹7.43 Cr
Pharmaceuticals & Biotechnology
4.54%
8
₹7.36 Cr
Pharmaceuticals & Biotechnology
4.49%
9
₹6.15 Cr
Pharmaceuticals & Biotechnology
3.76%
10
₹5.14 Cr
Healthcare Services
3.14%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 Tata Mutual Fund — Portfolio & Holdings
See all funds managed by Tata Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.